{"id":"https://openalex.org/W2767567733","doi":"https://doi.org/10.1002/pds.4343","title":"Safety assessment of niacin in the US Food and Drug Administration's mini\u2010sentinel system","display_name":"Safety assessment of niacin in the US Food and Drug Administration's mini\u2010sentinel system","publication_year":2017,"publication_date":"2017-11-06","ids":{"openalex":"https://openalex.org/W2767567733","doi":"https://doi.org/10.1002/pds.4343","mag":"2767567733","pmid":"https://pubmed.ncbi.nlm.nih.gov/29108128"},"language":"en","primary_location":{"id":"doi:10.1002/pds.4343","doi":"https://doi.org/10.1002/pds.4343","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.4343","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059157113","display_name":"Joshua J. Gagne","orcid":"https://orcid.org/0000-0001-5428-9733","observed_orcids":["https://orcid.org/0000-0001-5428-9733"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joshua J. Gagne","raw_affiliation_strings":["Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0001-5428-9733","affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077844359","display_name":"Monika Houstoun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monika Houstoun","raw_affiliation_strings":["Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019035108","display_name":"Marsha E. Reichman","orcid":"https://orcid.org/0000-0001-6963-1060","observed_orcids":["https://orcid.org/0000-0001-6963-1060"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marsha E. Reichman","raw_affiliation_strings":["Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"],"raw_orcid":"https://orcid.org/0000-0001-6963-1060","affiliations":[{"raw_affiliation_string":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047329021","display_name":"Christian Hampp","orcid":"https://orcid.org/0000-0002-1094-6364","observed_orcids":["https://orcid.org/0000-0002-1094-6364"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christian Hampp","raw_affiliation_strings":["Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104050181","display_name":"James H. Marshall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210111543","display_name":"Harvard Pilgrim Health Care","ror":"https://ror.org/01zxdeg39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210111543"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James H. Marshall","raw_affiliation_strings":["Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210111543"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067236770","display_name":"Sengwee Toh","orcid":"https://orcid.org/0000-0002-5160-0810","observed_orcids":["https://orcid.org/0000-0002-5160-0810"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210111543","display_name":"Harvard Pilgrim Health Care","ror":"https://ror.org/01zxdeg39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210111543"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sengwee Toh","raw_affiliation_strings":["Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-5160-0810","affiliations":[{"raw_affiliation_string":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210111543"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5059157113"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":2.0337,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.84580052,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"27","issue":"1","first_page":"30","last_page":"37"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/extended-release-niacin","display_name":"extended-release niacin","score":0.9599999785423279},{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.9559999704360962},{"id":"https://openalex.org/keywords/intracranial-hemorrhage","display_name":"intracranial hemorrhage","score":1.0},{"id":"https://openalex.org/keywords/laropiprant","display_name":"laropiprant","score":0.8360000252723694},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7160000205039978},{"id":"https://openalex.org/keywords/new-user-cohort","display_name":"new-user cohort","score":0.5329999923706055},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.7860000133514404},{"id":"https://openalex.org/keywords/claims-based-algorithm","display_name":"claims-based algorithm","score":0.5550000071525574}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.934744119644165},{"id":"https://openalex.org/C2780092750","wikidata":"https://www.wikidata.org/wiki/Q134658","display_name":"Niacin","level":2,"score":0.872278094291687},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7680598497390747},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.6279213428497314},{"id":"https://openalex.org/C2778080469","wikidata":"https://www.wikidata.org/wiki/Q1495657","display_name":"Gastrointestinal bleeding","level":2,"score":0.608374834060669},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5841513872146606},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5256306529045105},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5219930410385132},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4854743778705597},{"id":"https://openalex.org/C67774102","wikidata":"https://www.wikidata.org/wiki/Q614132","display_name":"Number needed to treat","level":4,"score":0.47029969096183777},{"id":"https://openalex.org/C167704817","wikidata":"https://www.wikidata.org/wiki/Q7295548","display_name":"Rate ratio","level":3,"score":0.4435698390007019},{"id":"https://openalex.org/C2778110834","wikidata":"https://www.wikidata.org/wiki/Q419724","display_name":"Fenofibrate","level":2,"score":0.4298247992992401},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.33625274896621704},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006471","descriptor_name":"Gastrointestinal Hemorrhage","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006471","descriptor_name":"Gastrointestinal Hemorrhage","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008076","descriptor_name":"Cholesterol, HDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D020300","descriptor_name":"Intracranial Hemorrhages","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D020300","descriptor_name":"Intracranial Hemorrhages","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/pds.4343","doi":"https://doi.org/10.1002/pds.4343","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.4343","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},{"id":"pmid:29108128","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29108128","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G5389459868","display_name":null,"funder_award_id":"HHSF223200910006I/HHSF22301007T","funder_id":"https://openalex.org/F4320332163","funder_display_name":"U.S. Food and Drug Administration"},{"id":"https://openalex.org/G8054393180","display_name":null,"funder_award_id":"HHSF223200910006I","funder_id":"https://openalex.org/F4320332163","funder_display_name":"U.S. Food and Drug Administration"}],"funders":[{"id":"https://openalex.org/F4320308849","display_name":"Kaiser Permanente","ror":"https://ror.org/00t60zh31"},{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W615260481","https://openalex.org/W1594888675","https://openalex.org/W1856460279","https://openalex.org/W1978071281","https://openalex.org/W1990598691","https://openalex.org/W2012487908","https://openalex.org/W2025542180","https://openalex.org/W2044507358","https://openalex.org/W2071854672","https://openalex.org/W2079491969","https://openalex.org/W2087018232","https://openalex.org/W2111207992","https://openalex.org/W2120242446","https://openalex.org/W2160420401","https://openalex.org/W2165605025","https://openalex.org/W2171252372","https://openalex.org/W2461501036","https://openalex.org/W2724923863"],"related_works":["https://openalex.org/W2969359395","https://openalex.org/W785948916","https://openalex.org/W2025468498","https://openalex.org/W2007510782","https://openalex.org/W7099768454","https://openalex.org/W2185930911","https://openalex.org/W2315295614","https://openalex.org/W2074620179","https://openalex.org/W2039517796","https://openalex.org/W1995314201"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1],"Heart":[2],"Protection":[3],"Study":[4],"2-Treatment":[5],"of":[6,12,21,31,62,71,76,136,154,163,189,239],"HDL":[7],"to":[8,48,56,84,106,118,133,172,202,212],"Reduce":[9],"the":[10,29,53,100,124],"Incidence":[11],"Vascular":[13],"Events":[14],"(HPS2-THRIVE)":[15],"trial":[16],"found":[17],"higher":[18],"incidence":[19],"rates":[20,61,135,188,238],"adverse":[22,44],"reactions,":[23],"including":[24],"bleeding,":[25],"in":[26,52,187,217],"patients":[27],"receiving":[28],"combination":[30],"extended-release":[32,57,72,113,158,233],"niacin":[33,73,114,159,234],"and":[34,66,74,143,220,237],"laropiprant":[35],"versus":[36,235],"placebo.":[37],"It":[38],"is":[39],"not":[40,50,226],"known":[41],"whether":[42],"these":[43],"events":[45,142],"are":[46],"attributable":[47],"laropiprant,":[49],"approved":[51],"USA,":[54],"or":[55,204,243],"niacin.":[58],"We":[59,79,92,224],"compared":[60],"major":[63,139,190,240],"gastrointestinal":[64,140,191,241],"bleeding":[65,141,192,242],"intracranial":[67,144,205,244],"hemorrhage":[68,145,206],"among":[69],"initiators":[70,75,160],"fenofibrate.":[77,122],"METHODS:":[78],"used":[80,128],"Mini-Sentinel":[81],"(now":[82],"Sentinel)":[83],"conduct":[85],"an":[86,230],"observational,":[87],"new":[88],"user":[89],"cohort":[90],"analysis.":[91],"included":[93],"data":[94],"from":[95,102],"5":[96],"Data":[97],"Partners":[98],"covering":[99],"period":[101],"January":[103],"1,":[104],"2007":[105],"August":[107],"31,":[108],"2013.":[109],"Individuals":[110],"who":[111,120],"initiated":[112,121],"were":[115,161,168,182,215],"propensity":[116,170,177],"score-matched":[117,171,178],"individuals":[119],"Within":[123],"matched":[125],"cohorts,":[126],"we":[127],"Cox":[129],"proportional":[130],"hazards":[131],"models":[132],"compare":[134],"hospitalization":[137],"for":[138,229],"assessed":[146],"using":[147],"validated":[148],"claims-based":[149],"algorithms.":[150],"RESULTS:":[151],"A":[152],"total":[153],"234":[155],"242":[156],"eligible":[157,173],"identified,":[162],"whom":[164],"210":[165],"389":[166],"(90%)":[167],"1:1":[169],"fenofibrate":[174,236],"initiators.":[175],"In":[176],"analyses,":[179],"no":[180],"differences":[181],"observed":[183],"between":[184,232],"exposure":[185],"groups":[186],"(hazard":[193],"ratio":[194],"[HR],":[195],"0.98;":[196],"95%":[197,209],"confidence":[198],"interval":[199],"[CI],":[200],"0.82":[201],"1.18)":[203],"(HR,":[207],"1.21;":[208],"CI,":[210],"0.66":[211],"2.22).":[213],"Results":[214],"similar":[216],"pre-specified":[218],"sensitivity":[219],"subgroup":[221],"analyses.":[222],"CONCLUSIONS:":[223],"did":[225],"observe":[227],"evidence":[228],"association":[231],"hemorrhage.":[245]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-11-17T00:00:00"}